<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537872</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR3789</org_study_id>
    <secondary_id>U01GH002115</secondary_id>
    <nct_id>NCT03537872</nct_id>
  </id_info>
  <brief_title>PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Lesotho</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University of Lesotho (NUL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROvide MIner-friendly SErvices for Integrated TB/HIV Care (PROMISE) study will assess
      the effectiveness, feasibility, and acceptability of integrated tuberculosis (TB)/HIV
      services provided in miner-friendly service venues in Lesotho that address barriers to early
      HIV diagnosis and antiretroviral therapy (ART) initiation, concurrent isoniazid preventive
      therapy (IPT), and retention in HIV care for migrant miners and their families in the context
      of President's Emergency Plan For AIDS Relief (PEPFAR) programming. The study will evaluate
      family-focused, integrated TB/HIV services for Basotho migrant miners and family members
      provided six days per week in miner-friendly service venues (MF), compared to public sector
      health facilities (PS), which will deliver usual integrated care for the management of TB and
      HIV.

      The ultimate goals of the project are to 1) improve health outcomes among migrant miners and
      their families, a hard-to-reach population that represents a hotspot of TB/HIV transmission,
      in Lesotho and in PEPFAR programs more broadly; and 2) strengthen the implementation science
      research capacity of national and local institutions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TB is the most common opportunistic infection and a leading cause of death among people
      living with HIV (PLHIV). Early ART and IPT have been shown to reduce TB incidence, morbidity,
      and mortality among PLHIV, including those with high CD4 counts, and are recommended by the
      World Health Organization (WHO) as core strategies to reduce the burden of TB among PLHIV.
      Basotho migrant miners, who travel between their homes in Lesotho and work in South African
      mines, and their families are at elevated risk of HIV and TB, however, their testing,
      engagement, and retention in care and treatment are suboptimal. Implementation science
      research is urgently needed to determine an effective strategy for improving early detection
      of HIV and early initiation of ART and IPT among migrant miners and their families.

      The PROMISE study is a mixed-methods implementation science study that will evaluate a
      miner-friendly intervention strategy to implement early ART and concurrent IPT for PLHIV. The
      study will assess the effectiveness, feasibility, and acceptability of integrated TB/HIV
      services for migrant miners and their family members provided in miner-friendly service
      venues (MF).

      A prospective cohort study design will be used to evaluate the effectiveness of
      family-focused, integrated TB/HIV services for Basotho migrant miners and family members
      provided six days per week in miner-friendly service venues, compared to public sector health
      facilities (PS), which will deliver usual integrated care for the management of TB and HIV.
      All participants will be assessed at the time of HIV testing (baseline), and at months 3, 6,
      and 9.

      Through implementing and measuring this enhanced TB/HIV service delivery model for miners and
      their families, study findings will have important implications on programs and policies
      broadly for PEPFAR, and specifically in Lesotho, for the organization and delivery of
      integrated TB/HIV services to migrant miners and their families. Findings will inform the
      development of more tailored interventions to promote HIV diagnosis, early ART, and IPT among
      miners with HIV, with possible implications for other types of mobile populations; enhance
      scientific awareness about the unique challenges facing miners in the context of their
      migration and high TB/HIV co-morbidity; and guide future efforts to develop differentiated
      service delivery models and integrated HIV/TB services in populations with a high prevalence
      of HIV and TB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">November 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of newly diagnosed HIV-positive participants initiated on ART (ART Initiation)</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>Participants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess ART initiation. This is designed to determine if participants at MF are more likely to initiate ART compared to those at PS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of newly diagnosed HIV-positive participants on ART initiated on IPT (IPT initiation)</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>Participants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess IPT initiation. This is designed to compare if participants on ART at MF are more likely to initiate IPT compared to those at PS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 count at enrollment</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>CD4 count at enrollment in care, collected from medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ART initiation</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>Time to ART initiation (in days) among newly diagnosed HIV-positive participants. Participants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess ART initiation date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to IPT initiation</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>Time to IPT initiation (in days) among newly diagnosed HIV-positive participants. Participants will complete interviewer-administered questionnaires and data will be abstracted from their medical records to assess IPT initiation date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of newly diagnosed HIV-positive participants initiated on ART retained in care at 6 and 9 months at original clinic</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>ART retention, collected from medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of newly diagnosed HIV-positive participants initiated on ART with plasma viral load &lt;1000 copies/ml at 6 months after ART initiation</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>Viral suppression, collected from medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants completed IPT among those who initiated IPT</measure>
    <time_frame>Up to 3 weeks after 9-month interview</time_frame>
    <description>IPT completion, collected from medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total prescribed doses of ART ingested, by self-report, averaged across study visits</measure>
    <time_frame>Up to 9 months post baseline interview</time_frame>
    <description>Participants will complete interviewer-administered questionnaires to assess ART adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of positive IsoScreen tests at the first study visit after IPT initiation</measure>
    <time_frame>Up to 9 months post baseline interview</time_frame>
    <description>Participants will submit a urine sample which will be used to perform a IsoScreen test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of total prescribed doses of IPT ingested, by self-report, averaged across study visits</measure>
    <time_frame>Up to 9 months post baseline interview</time_frame>
    <description>Participants will complete interviewer-administered questionnaires to assess IPT adherence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">641</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Miner-Friendly (MF) Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.
Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Public Sector (PS) Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.
Public Sector (PS) Health Facilities TB/HIV Integration Strategies</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies</intervention_name>
    <description>In addition to the control condition strategies (marked &quot;PS&quot;), the MF intervention includes additional strategies (marked &quot;MF&quot;):
STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)</description>
    <arm_group_label>Miner-Friendly (MF) Cohort</arm_group_label>
    <other_name>MF intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Public Sector (PS) Health Facilities TB/HIV Integration Strategies</intervention_name>
    <description>STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers</description>
    <arm_group_label>Public Sector (PS) Cohort</arm_group_label>
    <other_name>Control Condition (PS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MF Cohort Inclusion Criteria:

          -  Tested HIV-positive at MF site within one week of study enrollment

          -  Currently working or have worked in a South African mine, or are a family member of a
             miner (first-degree relative)

          -  Not on ART or IPT prior to testing HIV positive at the study site within the past week

          -  No history of IPT use

          -  15 years or older

          -  Basotho origin

          -  Capacity for consent

        MF Cohort Exclusion Criteria:

          -  Active TB

          -  Unwilling to provide a phone number or adhere to study procedures

        PS Cohort Inclusion Criteria:

          -  Tested HIV-positive at either the OPD or voluntary counseling and testing (VCT) clinic
             on-site within one week of study enrollment

          -  Not on ART or IPT prior to testing HIV positive at the study site within the past week

          -  No history of IPT use

          -  15 years or older

          -  Basotho origin

          -  Capacity for consent

        PS Cohort Exclusion Criteria:

          -  Tested HIV-positive at other points of service, including antenatal clinic, labor &amp;
             delivery, and TB clinics

          -  Active TB

          -  Unwilling to provide a phone number or adhere to study procedures

        Health Care Provider Inclusion Criteria:

          -  15 years or older

          -  Health care provider in MF or PS site

          -  Worked in the clinic for at least 3 months

          -  Capacity for consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea A. Howard, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICAP at Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koen Frederix, MBBS, MPH</last_name>
    <phone>+266-5887-0951</phone>
    <email>frederixk@icap.org.ls</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea A. Howard, MD, MS</last_name>
    <email>aah2138@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maputsoe Filter Clinic</name>
      <address>
        <city>Leribe</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palesa Makatise</last_name>
      <phone>+266-58028657</phone>
      <email>makatisep@icap.org.ls</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TEBA Leribe</name>
      <address>
        <city>Leribe</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palesa Makatise</last_name>
      <phone>+266-58028657</phone>
      <email>makatisep@icap.org.ls</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TEBA Mafeteng</name>
      <address>
        <city>Mafeteng</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palesa Makatise</last_name>
      <phone>+266-58028657</phone>
      <email>makatisep@icap.org.ls</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loretto Health Center</name>
      <address>
        <city>Maseru</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palesa Makatise</last_name>
      <phone>+266-58028657</phone>
      <email>makatisep@icap.org.ls</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TEBA Maseru</name>
      <address>
        <city>Maseru</city>
        <country>Lesotho</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palesa Makatise</last_name>
      <phone>+266-58028657</phone>
      <email>makatisep@icap.org.ls</email>
    </contact>
  </location>
  <location_countries>
    <country>Lesotho</country>
  </location_countries>
  <reference>
    <citation>Lesotho Ministry of Health, ICF International. Lesotho Demographic and Health Survey 2014. Key Indicators Report. Maseru; 2015.</citation>
  </reference>
  <reference>
    <citation>Global tuberculosis report 2016. Geneva, Switzerland: World Health Organization; 2016.</citation>
  </reference>
  <reference>
    <citation>Howard AA, Saito S, Frederix K, Hirsch-Moverman Y, Maama LB, Tau P, et al. Integrating TB/HIV Services for Migrant Miners and Their Families in Lesotho. Conference on Retroviruses and Opportunistic Infections February 22-25, 2016. Boston. Abstract 738.</citation>
  </reference>
  <reference>
    <citation>Stuckler D, Basu S, McKee M, Lurie M. Mining and risk of tuberculosis in sub-Saharan Africa. Am J Public Health. 2011 Mar;101(3):524-30. doi: 10.2105/AJPH.2009.175646. Epub 2010 Jun 1.</citation>
    <PMID>20516372</PMID>
  </reference>
  <reference>
    <citation>Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006 Mar 18;367(9514):926-37. Review.</citation>
    <PMID>16546541</PMID>
  </reference>
  <reference>
    <citation>Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010 May 15;50 Suppl 3:S201-7. doi: 10.1086/651492. Review.</citation>
    <PMID>20397949</PMID>
  </reference>
  <reference>
    <citation>Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS. 2010 Nov;24 Suppl 5:S5-13. doi: 10.1097/01.aids.0000391010.02774.6f.</citation>
    <PMID>21079429</PMID>
  </reference>
  <reference>
    <citation>Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013 Oct;13(10):852-8. doi: 10.1016/S1473-3099(13)70187-7. Epub 2013 Aug 16.</citation>
    <PMID>23954450</PMID>
  </reference>
  <reference>
    <citation>Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009 Mar 13;23(5):631-6. doi: 10.1097/QAD.0b013e328327964f.</citation>
    <PMID>19525621</PMID>
  </reference>
  <reference>
    <citation>Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007 Jul 11;21(11):1441-8.</citation>
    <PMID>17589190</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One. 2012;7(3):e34156. doi: 10.1371/journal.pone.0034156. Epub 2012 Mar 30.</citation>
    <PMID>22479548</PMID>
  </reference>
  <reference>
    <citation>Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, Mosimaneotsile B, Motsamai OI, Bozeman L, Davis MK, Talbot EA, Moeti TL, Moffat HJ, Kilmarx PH, Castro KG, Wells CD. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 May 7;377(9777):1588-98. doi: 10.1016/S0140-6736(11)60204-3. Epub 2011 Apr 12.</citation>
    <PMID>21492926</PMID>
  </reference>
  <reference>
    <citation>Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AM, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B, Ruff A. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014 Aug 8;9(8):e104557. doi: 10.1371/journal.pone.0104557. eCollection 2014.</citation>
    <PMID>25105417</PMID>
  </reference>
  <reference>
    <citation>INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.</citation>
    <PMID>26192873</PMID>
  </reference>
  <reference>
    <citation>TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni TD, Ahiboh H, Kabran M, Rabe C, Sidibé B, Nzunetu G, Konan R, Gnokoro J, Gouesse P, Messou E, Dohoun L, Kamagate S, Yao A, Amon S, Kouame AB, Koua A, Kouamé E, Ndri Y, Ba-Gomis O, Daligou M, Ackoundzé S, Hawerlander D, Ani A, Dembélé F, Koné F, Guéhi C, Kanga C, Koule S, Séri J, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatounde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Assi R, Bakayoko A, Mahassadi A, Attia A, Oussou A, Mobio M, Bamba D, Koman M, Horo A, Deschamps N, Chenal H, Sassan-Morokro M, Konate S, Aka K, Aoussi E, Journot V, Nchot C, Karcher S, Chaix ML, Rouzioux C, Sow PS, Perronne C, Girard PM, Menan H, Bissagnene E, Kadio A, Ettiegne-Traore V, Moh-Semdé C, Kouame A, Massumbuko JM, Chêne G, Dosso M, Domoua SK, N'Dri-Yoman T, Salamon R, Eholié SP, Anglaret X. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808-22. doi: 10.1056/NEJMoa1507198. Epub 2015 Jul 20.</citation>
    <PMID>26193126</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. Guidelines for intensifed tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva; WHO 2010.</citation>
  </reference>
  <reference>
    <citation>WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholders. Geneva: World Health Organization; 2012.</citation>
    <PMID>23586124</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. Policy brief: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: What's new. November 2015. Geneva; WHO 2015.</citation>
  </reference>
  <reference>
    <citation>Lesotho Ministry of Health. Global AIDS response progress report 2015: Lesotho country report. Reporting period January-December 2014. Maseru; 2015.</citation>
  </reference>
  <reference>
    <citation>World Health Organization. Global tuberculosis control 2015. Geneva; WHO; 2015. http://www.who.int/tb/publications/global_report/gtbr15_main_text.pdf. Accessed Jan 20, 2016.</citation>
  </reference>
  <reference>
    <citation>Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf; Accessed March 22, 2016.</citation>
  </reference>
  <reference>
    <citation>PEPFAR Scientific Advisory Board (SAB). Recommendations Regarding Provision of ART for all Persons Living with HIV (&quot;Test and START&quot;). http://www.pepfar.gov/documents/organization/250048.pdf. Accessed March 21, 2016.</citation>
  </reference>
  <reference>
    <citation>Joint United States Programme on HIV/AIDS (UNAIDS). The GAP Report. Geneva; 2014. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf. Accessed Jul 18, 2015.</citation>
  </reference>
  <reference>
    <citation>Abdissa HG, Lemu YK, Nigussie DT. HIV preventive behavior and associated factors among mining workers in Sali traditional gold mining site Bench Maji zone, Southwest Ethiopia: a cross sectional study. BMC Public Health. 2014 Sep 26;14:1003. doi: 10.1186/1471-2458-14-1003.</citation>
    <PMID>25256947</PMID>
  </reference>
  <reference>
    <citation>Campbell C. Migrancy, masculine identities and AIDS: the psychosocial context of HIV transmission on the South African gold mines. Soc Sci Med. 1997 Jul;45(2):273-81.</citation>
    <PMID>9225414</PMID>
  </reference>
  <reference>
    <citation>Corno L, de Walque D. Mines, migration and HIV/AIDS in southern Africa. J of African Economies 2012;21(3):465-498.</citation>
  </reference>
  <reference>
    <citation>International Organization for Migration. Country assessment on HIV prevention needs of migrants and mobile populations: Lesotho. Pretoria; 2010.</citation>
  </reference>
  <reference>
    <citation>Murray J, Davies T, Rees D. Occupational lung disease in the South African mining industry: research and policy implementation. J Public Health Policy. 2011;32 Suppl 1:S65-79. doi: 10.1057/jphp.2011.25.</citation>
    <PMID>21730995</PMID>
  </reference>
  <reference>
    <citation>Steele S. Human trafficking, labor brokering, and mining in southern Africa: responding to a decentralized and hidden public health disaster. Int J Health Serv. 2013;43(4):665-80.</citation>
    <PMID>24397233</PMID>
  </reference>
  <reference>
    <citation>Stuckler D, Steele S, Lurie M, Basu S. Introduction: 'dying for gold': the effects of mineral miningon HIV, tuberculosis, silicosis, and occupational diseases in southern Africa. Int J Health Serv. 2013;43(4):639-49. Review.</citation>
    <PMID>24397231</PMID>
  </reference>
  <reference>
    <citation>Martins-Fonteyn E, Loquiha O, Wouters E, Raimundo I, Hens N, Aerts M, Meulemans H. HIV Susceptibility Among Migrant Miners in Chokwe: A Case Study. Int J Health Serv. 2016 Oct;46(4):712-33. doi: 10.1177/0020731415585988. Epub 2015 May 19.</citation>
    <PMID>25995302</PMID>
  </reference>
  <reference>
    <citation>Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21. Review.</citation>
    <PMID>12742798</PMID>
  </reference>
  <reference>
    <citation>Basu S, Stuckler D, Gonsalves G, Lurie M. The production of consumption: addressing the impact of mineral mining on tuberculosis in southern Africa. Global Health. 2009 Sep 29;5:11. doi: 10.1186/1744-8603-5-11.</citation>
    <PMID>19785769</PMID>
  </reference>
  <reference>
    <citation>Rees D, Murray J, Nelson G, Sonnenberg P. Oscillating migration and the epidemics of silicosis, tuberculosis, and HIV infection in South African gold miners. Am J Ind Med. 2010 Apr;53(4):398-404. doi: 10.1002/ajim.20716.</citation>
    <PMID>19565628</PMID>
  </reference>
  <reference>
    <citation>Corbett EL, Churchyard GJ, Clayton TC, Williams BG, Mulder D, Hayes RJ, De Cock KM. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS. 2000 Dec 1;14(17):2759-68.</citation>
    <PMID>11125895</PMID>
  </reference>
  <reference>
    <citation>Fielding KL, Grant AD, Hayes RJ, Chaisson RE, Corbett EL, Churchyard GJ. Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials. 2011 May;32(3):382-92. doi: 10.1016/j.cct.2010.12.008. Epub 2010 Dec 28.</citation>
    <PMID>21193066</PMID>
  </reference>
  <reference>
    <citation>Vynnycky E, Sumner T, Fielding KL, Lewis JJ, Cox AP, Hayes RJ, Corbett EL, Churchyard GJ, Grant AD, White RG. Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol. 2015 Apr 15;181(8):619-32. doi: 10.1093/aje/kwu320. Epub 2015 Mar 19.</citation>
    <PMID>25792607</PMID>
  </reference>
  <reference>
    <citation>Gilbert JA, Long EF, Brooks RP, Friedland GH, Moll AP, Townsend JP, Galvani AP, Shenoi SV. Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa. PLoS One. 2015 May 4;10(5):e0126267. doi: 10.1371/journal.pone.0126267. eCollection 2015.</citation>
    <PMID>25938501</PMID>
  </reference>
  <reference>
    <citation>Kranzer K, van Schaik N, Karmue U, Middelkoop K, Sebastian E, Lawn SD, Wood R, Bekker LG. High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa. PLoS One. 2011;6(9):e25244. doi: 10.1371/journal.pone.0025244. Epub 2011 Sep 28.</citation>
    <PMID>21969875</PMID>
  </reference>
  <reference>
    <citation>Govender K, Akintola O, George G, Petersen I, Bhagwanjee A, Reardon C. Psychosocial and behavioural correlates of attitudes towards antiretroviral therapy (ART) in a sample of South African mineworkers. SAHARA J. 2011;8(2):55-64. doi: 10.1080/17290376.2011.9724986.</citation>
    <PMID>23237682</PMID>
  </reference>
  <reference>
    <citation>Bygrave H, Kranzer K, Hilderbrand K, Whittall J, Jouquet G, Goemaere E, Vlahakis N, Triviño L, Makakole L, Ford N. Trends in loss to follow-up among migrant workers on antiretroviral therapy in a community cohort in Lesotho. PLoS One. 2010 Oct 8;5(10):e13198. doi: 10.1371/journal.pone.0013198.</citation>
    <PMID>20976289</PMID>
  </reference>
  <reference>
    <citation>Barwise K, Lind A, Bennett R, Martins E. Intensifying action to address HIV and tuberculosis in Mozambique's cross-border mining sector. Int J Health Serv. 2013;43(4):699-719.</citation>
    <PMID>24397235</PMID>
  </reference>
  <reference>
    <citation>Currie CS, Williams BG, Cheng RC, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS. 2003 Nov 21;17(17):2501-8.</citation>
    <PMID>14600522</PMID>
  </reference>
  <reference>
    <citation>Lesotho National TB Programme. Maseru; 2013.</citation>
  </reference>
  <reference>
    <citation>Baleta A. Southern African declaration targets TB in mining sector. Lancet. 2012 Oct 6;380(9849):1217-8.</citation>
    <PMID>23057075</PMID>
  </reference>
  <reference>
    <citation>South African Development Community. Declaration on Tuberculosis in the Mining Sector. Maputo; 2012.</citation>
  </reference>
  <reference>
    <citation>Suphanchaimat R, Sommanustweechai A, Khitdee C, Thaichinda C, Kantamaturapoj K, Leelahavarong P, Jumriangrit P, Topothai T, Wisaijohn T, Putthasri W. HIV/AIDS health care challenges for cross-country migrants in low- and middle-income countries: a scoping review. HIV AIDS (Auckl). 2014 Feb 26;6:19-38. doi: 10.2147/HIV.S56277. eCollection 2014. Review.</citation>
    <PMID>24600250</PMID>
  </reference>
  <reference>
    <citation>Lesotho Ministry of Health. A situation analysis of miners and ex-miners affected and infected by tuberculosis: Lesotho. Maseru; 2012.</citation>
  </reference>
  <reference>
    <citation>Dahab M, Charalambous S, Hamilton R, Fielding K, Kielmann K, Churchyard GJ, Grant AD. &quot;That is why I stopped the ART&quot;: patients' &amp; providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health. 2008 Feb 18;8:63. doi: 10.1186/1471-2458-8-63.</citation>
    <PMID>18282286</PMID>
  </reference>
  <reference>
    <citation>Siu GE, Wight D, Seeley J. How a masculine work ethic and economic circumstances affect uptake of HIV treatment: experiences of men from an artisanal gold mining community in rural eastern Uganda. J Int AIDS Soc. 2012 Jun 14;15 Suppl 1:1-9. doi: 10.7448/IAS.15.3.17368.</citation>
    <PMID>22713356</PMID>
  </reference>
  <reference>
    <citation>Clinton Health Access Initiative. Health Findings and Recommendations: Domestic and Cross-Border Miners in Lesotho. Maseru; 2015.</citation>
  </reference>
  <reference>
    <citation>Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis. 2006 Jul;10(7):775-82.</citation>
    <PMID>16848340</PMID>
  </reference>
  <reference>
    <citation>Tavitian SM, Spalek VH, Bailey RP. A pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workers. Am J Health Syst Pharm. 2003 Sep 15;60(18):1856-61.</citation>
    <PMID>14521037</PMID>
  </reference>
  <reference>
    <citation>White MC, Tulsky JP, Goldenson J, Portillo CJ, Kawamura M, Menendez E. Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail. Arch Intern Med. 2002 May 13;162(9):1044-50.</citation>
    <PMID>11996616</PMID>
  </reference>
  <reference>
    <citation>White MC, Tulsky JP, Menendez E, Arai S, Goldenson J, Kawamura LM. Improving tuberculosis therapy completion after jail: translation of research to practice. Health Educ Res. 2005 Apr;20(2):163-74. Epub 2004 Aug 16.</citation>
    <PMID>15314035</PMID>
  </reference>
  <reference>
    <citation>White MC, Tulsky JP, Menendez E, Goldenson J, Kawamura LM. Incidence of TB in inmates with latent TB infection: 5-year follow-up. Am J Prev Med. 2005 Nov;29(4):295-301.</citation>
    <PMID>16242592</PMID>
  </reference>
  <reference>
    <citation>Chaisson RE, Barnes GL, Hackman J, Watkinson L, Kimbrough L, Metha S, Cavalcante S, Moore RD. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med. 2001 Jun 1;110(8):610-5.</citation>
    <PMID>11382368</PMID>
  </reference>
  <reference>
    <citation>Tulsky JP, Pilote L, Hahn JA, Zolopa AJ, Burke M, Chesney M, Moss AR. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med. 2000 Mar 13;160(5):697-702.</citation>
    <PMID>10724056</PMID>
  </reference>
  <reference>
    <citation>Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010 Nov;24 Suppl 5:S49-56. doi: 10.1097/01.aids.0000391022.95412.a6.</citation>
    <PMID>21079428</PMID>
  </reference>
  <reference>
    <citation>Diero L, Carter EJ, Silka A, Kimaiyo S, Gardner A, Yiannoutsos C, et al. The experience and outcomes of isoniazid preventive therapy in an HIV treatment program in Western Kenya. XVII International AIDS Conference 2008. Mexico City. Abstract MOAB0306; 2008.</citation>
  </reference>
  <reference>
    <citation>Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med. 2012;9(12):e1001351. doi: 10.1371/journal.pmed.1001351. Epub 2012 Dec 4. Review.</citation>
    <PMID>23226107</PMID>
  </reference>
  <reference>
    <citation>DiCarlo AL, Mantell JE, Remien RH, Zerbe A, Morris D, Pitt B, Abrams EJ, El-Sadr WM. 'Men usually say that HIV testing is for women': gender dynamics and perceptions of HIV testing in Lesotho. Cult Health Sex. 2014;16(8):867-82. doi: 10.1080/13691058.2014.913812. Epub 2014 May 22.</citation>
    <PMID>24854495</PMID>
  </reference>
  <reference>
    <citation>Shanaube K, Chaila JM, Floyd S, Schaap A, Griffith S, Hayes R, et al. Uptake of HIV Testing in the HPTN 071 (PopART) Trial in Zambia. Conference on Retroviruses and Opportunistic Infections February 22-25, 2016. Boston. Abstract 981.</citation>
  </reference>
  <reference>
    <citation>Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011 Dec;11(12):942-51. doi: 10.1016/S1473-3099(11)70181-5. Epub 2011 Oct 24. Review.</citation>
    <PMID>22030332</PMID>
  </reference>
  <reference>
    <citation>Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B, Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010 Nov 27;376(9755):1838-45. doi: 10.1016/S0140-6736(10)61997-6. Epub 2010 Nov 9.</citation>
    <PMID>21071074</PMID>
  </reference>
  <reference>
    <citation>Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, MacKeen L, Haberer J, Kimaiyo S, Sidle J, Ngare D, Bangsberg DR. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011 Mar 27;25(6):825-34. doi: 10.1097/QAD.0b013e32834380c1.</citation>
    <PMID>21252632</PMID>
  </reference>
  <reference>
    <citation>Emenyonu N MW, Habyarimana J, Pops-Eleches C, Thirumurthy H, Ragland K, Bangsberg DR. Cash transfers to cover clinic transportation costs improve retention in care in a HIV treatment program in rural Uganda. 17th Conference on Retroviruses and Opportunistic Infections 16-19 February 2010. San Francisco. Abstract 831.</citation>
  </reference>
  <reference>
    <citation>El Sadr W, Branson B, Hall HI, Beauchamp G, Donnell D, Torian L, et al. Effect of financial incentives on linkage to care and viral suppression: HPTN 065 (TLC-Plus) Study. Conference on Retroviruses and Opportunistic Infections 23-26 February 2015. Seattle. Abstract 29.</citation>
  </reference>
  <reference>
    <citation>Etienne M, Burrows L, Osotimehin B, Macharia T, Hossain B, Redfield RR, Amoroso A. Situational analysis of varying models of adherence support and loss to follow up rates; findings from 27 treatment facilities in eight resource limited countries. Trop Med Int Health. 2010 Jun;15 Suppl 1:76-81. doi: 10.1111/j.1365-3156.2010.02513.x.</citation>
    <PMID>20586964</PMID>
  </reference>
  <reference>
    <citation>South African Development Community. Policy framework for population mobillity and communicable diseases in the SADC region. Gaborone; 2009.</citation>
  </reference>
  <reference>
    <citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.</citation>
    <PMID>11556941</PMID>
  </reference>
  <reference>
    <citation>Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14;158(16):1789-95.</citation>
    <PMID>9738608</PMID>
  </reference>
  <reference>
    <citation>Group GGATSC. Tobacco Questions for Surveys: A Subset of Key Questions from the Global Adult Tobacco Survey (GATS), 2nd Edition. Atlanta, GA: Centers for Disease Control and Prevention; 2011.</citation>
  </reference>
  <reference>
    <citation>Kalichman SC, Simbayi LC, Jooste S, Toefy Y, Cain D, Cherry C, Kagee A. Development of a brief scale to measure AIDS-related stigma in South Africa. AIDS Behav. 2005 Jun;9(2):135-43.</citation>
    <PMID>15933833</PMID>
  </reference>
  <reference>
    <citation>Brock DM, Sarason IG, Sarason BR, Pierce GR. Simultaneous assessment of perceived global and relationship-specific support. Journal of Social and Personal Relationships 1996;13:143-152.</citation>
  </reference>
  <reference>
    <citation>Lubogo D, Ddamulira JB, Tweheyo R, Wamani H. Factors associated with access to HIV care services in eastern Uganda: the Kumi home based HIV counseling and testing program experience. BMC Fam Pract. 2015 Nov 3;16:162. doi: 10.1186/s12875-015-0379-6.</citation>
    <PMID>26530286</PMID>
  </reference>
  <reference>
    <citation>WHO Multi-Country Study on Women's Health and Domestic Violence: core questionnaire and WHO instrument, version 9. Geneva, Switzerland: World Health Organization; 2000.</citation>
  </reference>
  <reference>
    <citation>Dunkle KL, Jewkes RK, Brown HC, Yoshihama M, Gray GE, McIntyre JA, Harlow SD. Prevalence and patterns of gender-based violence and revictimization among women attending antenatal clinics in Soweto, South Africa. Am J Epidemiol. 2004 Aug 1;160(3):230-9.</citation>
    <PMID>15257996</PMID>
  </reference>
  <reference>
    <citation>Wilson IB, Lee Y, Michaud J, Fowler FJ Jr, Rogers WH. Validation of a New Three-Item Self-Report Measure for Medication Adherence. AIDS Behav. 2016 Nov;20(11):2700-2708.</citation>
    <PMID>27098408</PMID>
  </reference>
  <reference>
    <citation>IsoScreen. Oxfordshire, UK: GFC Diagnostic Ltd.</citation>
  </reference>
  <reference>
    <citation>Whitfield R, Cope GF. Point-of-care test to monitor adherence to anti-tuberculous treatment. Ann Clin Biochem. 2004 Sep;41(Pt 5):411-3.</citation>
    <PMID>15333195</PMID>
  </reference>
  <reference>
    <citation>Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, Chaisson RE, Golub JE. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med. 2010 May;104(5):754-7. doi: 10.1016/j.rmed.2010.02.001. Epub 2010 Mar 3.</citation>
    <PMID>20202806</PMID>
  </reference>
  <reference>
    <citation>Mkopi A, Range N, Lwilla F, Egwaga S, Schulze A, Geubbels E, van Leth F. Adherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania. PLoS One. 2012;7(12):e51828. doi: 10.1371/journal.pone.0051828. Epub 2012 Dec 19.</citation>
    <PMID>23284782</PMID>
  </reference>
  <reference>
    <citation>van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011 Sep 1;89(9):632-9. doi: 10.2471/BLT.11.086462. Epub 2011 May 20.</citation>
    <PMID>21897483</PMID>
  </reference>
  <reference>
    <citation>Patton MW. Developing a time motion study for a lean healthcare environment: University of Kentucky; 2011.</citation>
  </reference>
  <reference>
    <citation>Corbin J, Strauss A. Grounded theory research: Procedures, canons, and evaluative criteria. Qualitative Sociology 1990;13:3-21.</citation>
  </reference>
  <reference>
    <citation>Howard AA, Hirsch-Moverman Y, Frederix K, Daftary A, Saito S, Gross T, Wu Y, Maama LB. The START Study to evaluate the effectiveness of a combination intervention package to enhance antiretroviral therapy uptake and retention during TB treatment among TB/HIV patients in Lesotho: rationale and design of a mixed-methods, cluster-randomized trial. Glob Health Action. 2016 Jun 27;9:31543. doi: 10.3402/gha.v9.31543. eCollection 2016.</citation>
    <PMID>27357074</PMID>
  </reference>
  <reference>
    <citation>Howard AA, Hirsch-Moverman Y, Saito S, Gadisa T, Daftary A, Melaku Z. The ENRICH Study to evaluate the effectiveness of a combination intervention package to improve isoniazid preventive therapy initiation, adherence and completion among people living with HIV in Ethiopia: rationale and design of a mixed methods cluster randomized trial. Contemp Clin Trials Commun. 2017 Jun;6:46-54. doi: 10.1016/j.conctc.2017.03.001. Epub 2017 Mar 16.</citation>
    <PMID>28626811</PMID>
  </reference>
  <reference>
    <citation>Pathways to Engagement in HIV-Care for Newly Diagnosed South Africans, R01-MH83561, 2009-2014, Susie Hoffman DrPH, PI.</citation>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Andrea Howard</investigator_full_name>
    <investigator_title>Associate Professor of Epidemiology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>ICAP will make de-identified datasets from this project publically available, per CDC requirements.
The dataset includes: 1) Routinely collected aggregate data from all patients undergoing HIV testing, including number tested for HIV, number testing HIV-positive, and number linked to care, stratified by sex and age; 2) Data collected from cohort participants in the miner-friendly service venue (MF) and public sector facility (PS) conditions, including a baseline interview, 3-, 6- and 9-month follow-up interviews, time-motion assessments, IsoScreen test results to measure adherence to IPT, and medical record abstraction of HIV clinic records; 3) Data collected from MF participants only, including in-depth interviews with miners and family members and health care providers; and 4) Data collected from all study sites, including a monthly site assessment of program characteristics and prospective data on service delivery costs.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

